Want to see AU:1AI full AI Analyst Report?
Top Page
Living Cell Technologies
(Sydney:1AI)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Downgraded
Date:09/06/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn), with some mitigation from having no reported debt. Technicals add modest downside pressure due to price trading below key moving averages and negative MACD. Valuation remains constrained because the company is loss-making and offers no dividend support.
Positive Factors
Debt-Free Balance Sheet
No reported debt reduces fixed financial obligations and lowers exposure to refinancing or interest-cost pressure. That gives management greater flexibility to allocate available capital toward research and development, while providing some resilience if development timelines extend.
Negative Factors
No Reported Revenue
The absence of reported revenue means the business has not yet demonstrated commercial traction or an operating revenue base. This leaves future funding and value creation dependent on successful program development, regulatory progress, and eventual commercialization rather than established customer demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
No reported debt reduces fixed financial obligations and lowers exposure to refinancing or interest-cost pressure. That gives management greater flexibility to allocate available capital toward research and development, while providing some resilience if development timelines extend.
Read all positive factors
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$22.30M
Dividend YieldN/A
Average Volume (3M)628.00K
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue GrowthN/A
EPS Growth-200.00%
CountryAU
Employees48
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,027,571,000
10 Day Avg. Volume691,856
30 Day Avg. Volume627,996
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-6.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Living Cell Technologies Business Overview & Revenue Model
Company Description
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primaril...
How the Company Makes Money
null...
Living Cell Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2024 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -557.00 | -743.00 |
| EBITDA | -2.04M | -3.14M | -1.54M | -2.10M | -2.13M | -2.38M |
| Net Income | -1.01M | -2.71M | -802.96K | -2.10M | -2.11M | -1.96M |
Balance Sheet | ||||||
| Total Assets | 2.00M | 4.44M | 2.40M | 5.49M | 6.23M | 4.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.88M | 3.94M | 2.32M | 3.11M | 6.13M | 7.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.25K | 176.72K | 169.76K | 178.45K | 449.86K | 239.26K |
| Stockholders Equity | 1.89M | 4.26M | 2.23M | 3.01M | 3.76M | 4.03M |
Cash Flow | ||||||
| Free Cash Flow | -702.90K | -2.60M | -785.25K | -1.52M | -1.99M | -2.05M |
| Operating Cash Flow | -702.90K | -2.60M | -785.25K | -1.52M | -1.99M | -2.04M |
| Investing Cash Flow | 1.35M | 1.10M | 450.00K | -277.44K | 0.00 | 39.50K |
| Financing Cash Flow | 179.59K | 4.22M | -3.00K | 523.00K | 1.85M | 4.69M |
Living Cell Technologies Technical Analysis
Positive
0.01
Price Trends
Market Momentum
68.35
Neutral
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:1AI, the sentiment is Positive. The current price of 0.01 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at 68.35 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:1AI.
Living Cell Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$3.09B | -23.30 | -16.10% | ― | 555.67% | 49.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
49 Neutral | AU$196.08M | -13.58 | -36.83% | ― | 51.07% | -47.63% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% | |
41 Neutral | AU$2.68M | -0.29 | -607.23% | ― | ― | 15.04% | |
40 Underperform | AU$22.30M | -11.00 | -88.14% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:1AI
Living Cell Technologies
0.01
<0.01
10.00%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.18
-94.74%
AU:MSB
Mesoblast Limited
2.23
-0.01
-0.45%
AU:OCC
Orthocell Ltd
0.73
-0.41
-35.96%
AU:TRP
Tissue Repair Ltd
0.08
-0.22
-73.33%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-10.68%
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals Lapses 10 Million Performance Rights After Unmet Conditions
Sep 2, 2026
Algorae Pharmaceuticals Limited has notified the ASX of the cessation of 10,000,000 performance rights after the underlying conditions failed to be met or became incapable of being satisfied. The lapse of these conditional securities reduces the c...
Algorae Pharmaceuticals Files ASX Corporate Governance Statement for 2026
Aug 31, 2026
Algorae Pharmaceuticals has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with key ASX Corporate Governance Council principles. The statement, approved as of 31 August 2026 and published on...
Algorae Pharmaceuticals Losses Deepen as Commercial Operations Expand
Aug 31, 2026
Algorae Pharmaceuticals Limited reported a sharp deterioration in its full-year financial performance to 30 June 2026, with total revenue and other income falling 45% to $77,667. The group booked no service revenue and again paid no dividends, und...
Algorae bolsters board with Nasdaq pharmaceutical chairman Troy Valentine
Jul 14, 2026
Algorae Pharmaceuticals has appointed Nasdaq pharmaceutical chairman Troy Valentine as a Non-Executive Director, effective 14 July 2026, as part of a broader board renewal program. His appointment follows the resignation of director Brad Dilkes an...
Algorae Pharmaceuticals Issues 2 Million New Shares Under Cleansing Notice
Jul 6, 2026
Algorae Pharmaceuticals has issued 2,000,000 fully paid ordinary shares on 6 July 2026, notifying the market via a cleansing notice under section 708A(5)(e) of the Corporations Act. The company states that the shares were issued without a disclosu...
Algorae Pharmaceuticals Seeks ASX Quotation for 2 Million New Shares
Jul 6, 2026
Algorae Pharmaceuticals Limited has applied for quotation of 2,000,000 ordinary fully paid shares on the Australian Securities Exchange. The new securities, to be issued under the ASX code 1AI on July 6, 2026, expand the company’s listed cap...
AlgoraeOS v2 Wins Independent Validation for Cancer Drug Synergy Predictions
Jul 2, 2026
Algorae Pharmaceuticals has reported positive independent preclinical validation of its AlgoraeOS v2 drug-combination prediction platform at the Peter MacCallum Cancer Centre. The study evaluated 24 CBD drug combinations across four cancer cell li...
Algorae Wins NSW Health Hospital Supply Deal in Key Commercial Milestone
Jul 1, 2026
Algorae Pharmaceuticals has secured a public hospital supply contract with NSW Health following a competitive tender, marking a significant commercial milestone for its AlgoraeRx division. The initial three-year agreement, with two optional one-ye...
Algorae Pharmaceuticals appoints joint company secretaries as it advances AI-driven drug strategy
Jun 30, 2026
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical group listed on the ASX that combines advanced drug-combination discovery with a growing commercial medicines business. Its AlgoraeOS platform uses machine learning to identify synergisti...
Algorae Joins Sovereign AI Infrastructure as Healthcare Launch Partner
Jun 28, 2026
Algorae Pharmaceuticals has been selected as a foundation participant and the healthcare and life sciences launch partner for the new Sovereign AI Infrastructure initiative, led by AgenticScale.ai and powered by NVIDIA-accelerated technology. The ...
Algorae Pharmaceuticals switches auditors to address independence concerns
Jun 24, 2026
Algorae Pharmaceuticals has appointed PKF Perth as its new external auditor, following the resignation of PKF Brisbane Audit and consent from the Australian Securities and Investments Commission. The change is motivated by auditor independence con...
Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice
Jun 19, 2026
Algorae Pharmaceuticals has issued a new tranche of fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the small-scale offering provisions of the Corporations Act. The company ...
Algorae Pharmaceuticals Plans Placement of 2 Million New Shares
Jun 16, 2026
Algorae Pharmaceuticals has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares under a new placement or similar capital-raising structure. The securities are expected to be issued on 16 June 2026, signalling an addi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.